Gilead Sciences is nearing a deal to buy biotech Immunomedics.
Breaking news from The Wall Street Journal
News Alert | Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion |
|
| Gilead Sciences is nearing a deal to buy biotech Immunomedics and its prized breast-cancer drug for more than $20 billion, according to people familiar with the matter. |
| | Read WSJ's latest headlines › | |
|
|